TG01 (Targovax), a peptide vaccine derived from KRAS-mutant proteins, has been tested in phase I trials of patients with multiple myeloma [49] and resected pancreatic cancer [50,51]. This evidence concerns the gene KRAS and familial pancreatic carcinoma.